Back to search
Resectable Hepatocellular Carcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Resectable Hepatocellular Carcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Resectable Hepatocellular Carcinoma trials you may qualify forThe goal of this clinical trial is to learn if the neoadjuvant therapy of iIparomlimab and Tuvonralimab plus lenvatinib works to treat hepatocellular carcinoma(…
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, being the third leading cause of cancer-related death worldwide, with approximately 745…
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un…
This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurre…
Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the es…
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple type…
This study explores the potential values of a new blood test approach to detect measurable residual disease or early coming back of cancer (recurrence)/cancer g…
This is an open-label, single-arm, phase 2 study evaluating hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and cadonilimab as conversion…